Form 4: Kymera Therapeutics CFO Bruce N. Jacobs Reports Stock Transactions
SEC Form 4 Filing
Bruce N. Jacobs, CFO of Kymera Therapeutics, reports the acquisition and disposal of common stock and stock options related to vesting restricted stock units.
Summary
- On March 3, 2025, Bruce N. Jacobs, the Chief Financial Officer of Kymera Therapeutics, reported transactions involving the company's common stock and stock options.
- Jacobs acquired 30,000 shares of common stock through restricted stock units (RSUs) at a price of $0.
- He also sold 5,754 shares at a weighted average price of $30.3271 and 1,281 shares at a weighted average price of $31.0046 to cover tax withholding obligations related to the vesting of RSUs.
- Additionally, Jacobs acquired a stock option to buy 60,000 shares of common stock at an exercise price of $30.17.
- Following these transactions, Jacobs beneficially owns 201,886 shares of common stock and stock options for 60,000 shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity related to compensation.
Future Outlook
The RSUs vest in three equal annual installments, and the stock options vest in 36 equal monthly installments, both contingent upon continued employment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
- The disclosure provides transparency to shareholders regarding insider trading activities.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of earliest transaction, grant of RSUs and stock options, and sale of shares for tax obligations. |
| 03/02/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.